Welcome to our dedicated page for FSD Pharma news (Ticker: $HUGE), a resource for investors and traders seeking the latest updates and insights on FSD Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FSD Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FSD Pharma's position in the market.
Rhea-AI Summary
FSD Pharma and Celly Nutrition Corp. enter into an agreement for the distribution of FSD Pharma's shareholdings of Celly Nu to certain securityholders of FSD Pharma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
-
Rhea-AI Summary
The Ontario Superior Court of Justice has dismissed the motion to set aside the arbitration award to FSD Pharma filed by Dr. Raza Bokhari, the former CEO of FSD Pharma and current CEO of Medicus Pharma. FSD Pharma has been awarded approximately CDN$2.81 million in costs of arbitration. The Court also ordered Dr. Bokhari to pay FSD Pharma $175,000 to cover its legal costs for his failed set aside motion. FSD Pharma will vigorously pursue to collect the monetary awards and all accruing interest at a rate of 6%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
-
Rhea-AI Summary
FSD Pharma continues development of UNBUZZD™ rapid detox drink. Kevin Harrington endorses the product. Positive market potential with global hangover cure products market projected to reach US $6.2 billion by 2030. Interim results for Lucid-MS Phase I trial show well tolerance. Shares trading at US$1.40 on NASDAQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.76%
Tags
Rhea-AI Summary
FSD Pharma receives interim report for Phase I trial of Lucid-MS, a potential treatment for Multiple Sclerosis. Lucid-21-302 demonstrated safety and well-tolerance in healthy volunteers. Positive results for further development activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
-
Rhea-AI Summary
FSD Pharma receives analyst coverage from Singular Research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
-
Rhea-AI Summary
FSD Pharma provides clarity and rebuttal to claims made by GBB Drink Lab regarding their development of an alcohol detoxification drink. FSD Pharma believes GBB's claims are untrue and demonstrate a lack of understanding. FSD Pharma will vigorously defend against the lawsuit and continues to work on their own alcohol detoxification products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
FSD Pharma Inc. announces its late breaking abstract about Phase 1 first-in-human data on Lucid-MS was selected for presentation at the upcoming MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS meeting. Lucid-MS is a potential drug candidate for multiple sclerosis (MS) targeting demyelination in the central nervous system. FSD Pharma will present Phase 1 data on the safety, tolerability, and pharmacokinetics of Lucid-21-302 in healthy volunteers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.14%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
-
Rhea-AI Summary
FSD Pharma has signed a definitive agreement with Celly Nutrition to grant exclusive rights to recreational applications for FSD Pharma's alcohol misuse technology and launch UNBUZZD, a rapid alcohol detoxification drink. The global hangover cure products market is expected to reach $6.18 billion by 2030. The launch of UNBUZZD is seen as a major milestone for FSD Pharma. The company will receive a 7% royalty on revenue from Celly Nutrition until $250 million has been paid, and has also been issued 100 million common shares and an anti-dilution warrant. FSD Pharma will loan Celly Nutrition $1 million on a secured basis with a 10% interest rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
Rhea-AI Summary
FSD Pharma announces that an arbitration panel has found that Syneos Health failed to use commercially reasonable efforts in conducting its trial for FSD 201. Syneos Health had filed a claim against FSD Pharma, seeking damages of USD$3,915,388.69 for a failed Phase II FDA trial. The panel awarded Syneos Health $1,707,830.52 in damages plus interest. FSD Pharma countersued Syneos Health for breach of contract.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FSD Pharma Inc.
Nasdaq:HUGE
HUGE Rankings
HUGE Stock Data
12.74M
34.34M
17.37%
2.53%
0.82%
Medicinal and Botanical Manufacturing
Manufacturing
United States of America
Toronto
About HUGE
fsd pharma inc., through its subsidiary, fv pharma inc., produces medical cannabis in canada. the company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, gi tract, and musculoskeletal system, such as chronic pain. fsd pharma inc. has strategic alliance agreements with scicann therapeutics inc., canntab therapeutics, and solarvest bioenergy inc. the company was founded in 1998 and is headquartered in toronto, canada.